NKTR Nektar Therapeutics

0  -2%
Previous Close 22.89
Open 22.86
Price To book 39.81
Market Cap 3.47B
Shares 153,831,000
Volume 2,832,095
Short Ratio 8.35
Av. Daily Volume 1,715,380

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 1H 2017.
Cipro DPI
Phase 3 data released March 20, 2017 - endpoints met.
Lower back pain
Phase 1/2 initial data due mid-2017.
Solid tumors - cancer
Phase 3 data due mid-2017.
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
Phase 3 topline data mid March 2015 did not reach primary endpoint.
Etirinotecan pegol NKTR-102 (BEACON)
Cancer - Metastatic Breast Cancer
Approved November 16, 2015.
Hemophilia A
Approved September 16, 2014.
MOVANTIK (Naloxegol)
Opioid-induced constipation (OIC)
Phase 3 data released December 12, 2016 - primary endpoint not met.

Latest News

  1. Could Nektar Therapeutics Be Worth More?
  2. 4 Biotech Stocks to Watch
  3. Nektar Therapeutics (NKTR): Here’s What Just Happened
  4. Nektar's Pain Drug Positive in Phase III Study; Shares Gain
  5. Stocks of Nektar Therapeutics and CytomX Therapeutics Rise on FDA Trial News
  6. Biotech Hits 11-Year High On Potential To Dethrone Oxycodone
  7. Nektar Pharma Opioid Drug Shows Promise In Phase 3
  8. Nektar, AMD, Esperion, and More: Here’s Why These Five Stocks Are Surging
  9. A new painkiller is being designed that won't get users high, and it could save thousands of lives
  10. Why Nektar Therapeutics Inc. Is Rising Today
  11. Monday’s Top Biopharma Movers
  12. Biotech Premarket Movers: CytomX, Aevi, Esperion
  13. Nektar Therapeutics' stock jumps after positive results of its pain treatment drug
  14. NEKTAR THERAPEUTICS Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  15. Nektar's opioid painkiller succeeds in key late-stage study
  16. NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain
  17. Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study
  18. Nektar Surges by Most Since 1996 After Opioid Trial Success
  20. Nektar Therapeutics :NKTR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 3, 2017